160 related articles for article (PubMed ID: 25904322)
21. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
Kobayashi T; Inoue Y; Morikawa A
Nihon Rinsho; 2008 Feb; 66(2):332-7. PubMed ID: 18260333
[TBL] [Abstract][Full Text] [Related]
22. Kawasaki disease shock syndrome: a severe form of Kawasaki disease.
İşgüder R; Doksöz Ö; Bağ Ö; Ağın H; Meşe T; Karaarslan ÜU; Devrim İ
Turk J Pediatr; 2013; 55(3):319-21. PubMed ID: 24217080
[TBL] [Abstract][Full Text] [Related]
23. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
Li X; Chen Y; Tang Y; Ding Y; Xu Q; Sun L; Qian W; Qian G; Qin L; Lv H
Eur J Pediatr; 2018 Aug; 177(8):1279-1292. PubMed ID: 29948255
[TBL] [Abstract][Full Text] [Related]
24. [Kawasaki syndrome in adults: treatment with polyvalent intravenous immunoglobulins].
Pavese P; Brion JP; Meusnier T; Stahl JP
Ann Med Interne (Paris); 1997; 148(3):287-8. PubMed ID: 9255342
[No Abstract] [Full Text] [Related]
25. Immunoglobulin resistance in Kawasaki disease with chronic granulomatous disease.
Tsuge M; Shigemitsu Y; Yano Y; Fujiwara M; Miyai T; Ueda K; Takata K; Moriwake T
Pediatr Int; 2012 Jun; 54(3):e32-4. PubMed ID: 22631588
[No Abstract] [Full Text] [Related]
26. Typical Kawasaki disease with atypical pneumonia: a paediatric case report.
Maggio MC; Cimaz R; Failla MC; Dones P; Corsello G
Scand J Rheumatol; 2021 May; 50(3):248-249. PubMed ID: 32804000
[No Abstract] [Full Text] [Related]
27. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.
Jang H; Kim KY; Kim DS
Yonsei Med J; 2018 Jan; 59(1):113-118. PubMed ID: 29214785
[TBL] [Abstract][Full Text] [Related]
29. Prediction of intravenous immunoglobulin-resistant Kawasaki disease: a research hotspot.
Xu B; Zhang Q; Du J; Shiraishi I; Jin H
Sci Bull (Beijing); 2023 Jan; 68(2):121-124. PubMed ID: 36681588
[No Abstract] [Full Text] [Related]
30. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).
;
Pediatr Int; 2014 Apr; 56(2):135-58. PubMed ID: 24730626
[No Abstract] [Full Text] [Related]
31.
Kwon YC; Kim JJ; Yun SW; Yu JJ; Yoon KL; Lee KY; Kil HR; Kim GB; Han MK; Song MS; Lee HD; Ha KS; Sohn S; Hong YM; Jang GY; Lee JK;
Circ Genom Precis Med; 2018 Feb; 11(2):e002020. PubMed ID: 29453247
[No Abstract] [Full Text] [Related]
32. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
33. Length of hospital stay with prednisolone or cyclosporine for Kawasaki disease.
Watanabe Y; Ikeda H; Watanabe T; Onuki Y; Iwaku T
Pediatr Int; 2023; 65(1):e15673. PubMed ID: 38009989
[No Abstract] [Full Text] [Related]
34. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
Hu JW; Zhou ZS; Yang L; Zheng CN; Wang KD
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1259-64. PubMed ID: 21756798
[TBL] [Abstract][Full Text] [Related]
36. Arthritis in Kawasaki disease after responding to intravenous immunoglobulin treatment.
Lee KY; Oh JH; Han JW; Lee JS; Lee BC
Eur J Pediatr; 2005 Jul; 164(7):451-2. PubMed ID: 15782294
[No Abstract] [Full Text] [Related]
37. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
Pagnini I; Marino A; Simonini G; Cimaz R
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S170. PubMed ID: 22410254
[No Abstract] [Full Text] [Related]
38. Lessons from Kawasaki disease: all brands of IVIG are not equal.
Stiehm ER
J Pediatr; 2006 Jan; 148(1):6-8. PubMed ID: 16423589
[No Abstract] [Full Text] [Related]
39. [Updates on diagnosis and management of Kawasaki disease unresponsive to intravenous gamma globulin].
Wang YQ; Cao XJ
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):226-8. PubMed ID: 15833210
[No Abstract] [Full Text] [Related]
40. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease.
Nakagawa M; Watanabe N; Okuno M; Kondo M; Okagawa H; Taga T
Am J Hematol; 2000 Mar; 63(3):160-1. PubMed ID: 10679809
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
